Bone mineral density and body composition in Noonan's syndrome: effects of growth hormone treatment

J Pediatr Endocrinol Metab. 2002 Jan;15(1):81-7. doi: 10.1515/jpem.2002.15.1.81.

Abstract

We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Adipose Tissue / pathology
  • Adolescent
  • Biomarkers
  • Body Composition / drug effects
  • Body Composition / physiology*
  • Bone Density / drug effects
  • Bone Density / physiology*
  • Child
  • Electric Impedance
  • Female
  • Growth Hormone / therapeutic use*
  • Humans
  • Male
  • Noonan Syndrome / drug therapy*
  • Noonan Syndrome / pathology*

Substances

  • Biomarkers
  • Growth Hormone